Editor’s Note: Today marks the inaugural issue of our newest membership benefit, The Porter & Co. Spotlight. If you missed our announcement explaining the Spotlight, you can read it here.
On Mondays we’ll turn the spotlight outside of Porter & Co. We’ll bring you exclusive access to the research, the thinking, and the investment ideas of the analysts who Porter follows.
Each month we’ll focus on an analyst not part of the Porter & Co. family whose work Porter thinks you need to be aware of, and that he believes could make a big difference to your finances.
These will be analysts who Porter has known and followed for years, if not decades and whose ideas and insights have withstood the test of time. We kick off this new membership series with one of Porter’s first mentors.
It was David Lashmet’s initial day at work.
He was my first editorial hire at Stansberry Research, back in winter of 2000.
I picked Dave up from the airport in D.C. We raced to the offices of Celera Genomics, where Craig C. Venter was about to finish sequencing the first full human genome.
We met with Craig and, even more importantly, sat down with Celera’s IT team, the computer scientists from Paracel and got a tour of the giant parallel computer they’d built to run Celera’s gene-matching software.
Thus, from Dave’s very first day working with me, we could see, directly in front of us, the road map for technological evolution in both medicine and computers.
A few weeks later, Celera announced it had completed the first full human genome sequence. And, as you know, parallel architecture is now at the heart of the entire NVIDIA-led revolution in computing.
I’d hired Dave because he was, by far, the most brilliant researcher I’d ever met and my very best professor in college.
But I could not have imagined all he would accomplish for investors since joining up with me, including being the first investor I know to recognize the incredible changes that Nvidia would bring to the world.
However, Dave’s enormous profits with Nvidia weren’t even close to the biggest gains he’s helped people make.
He has consistently helped his readers get in on some of the world’s best performing companies, usually years before the mainstream financial press catches wind of them.
That’s why, when it came to launching our new “guest” editor content called Porter & Co. Spotlight, Dave was the first expert I wanted to bring to you.
Because if there’s one person outside of the Porter & Co. team who I believe can benefit you the most, it’s Dave Lashmet.
What he does is simple, but very difficult to execute.
He doesn’t follow companies, he follows the evolution of technology by reading scientific journals, by going to scientific conferences, and by building an incredible network of bench scientists.
That’s what enabled him, for example, to pick Novo Nordisk years ago — long before anyone else had ever heard of GLP-1 drugs.
It’s also why he is among the best analysts to show you how to profit from the next phase of the GLP-1 weight loss revolution.
In this special editorial report, Dave will walk you through how to profit – and keep profiting – from one of the most important drug discoveries in the world.
You can go here to read it now.
In future Spotlights, we’ll explore other transformational drugs that Dave and his team have uncovered, and show you how they could deliver massive returns for early investors.
For today though, enjoy this investigation into the future of GLP-1 drugs from the man who spotted them before anyone else.
The advantage that Dave can give you in the markets is hard to imagine, unless you’ve experienced it. And so, I’ve asked Dave to show you how he does the impossible: predict the future.
Porter
P.S. I also recently invited Dave to the farm to discuss the future of these drugs, how to best invest in them, and what he’s most excited about in the years ahead. You can watch it here.